NO893149L - Fremgangsmaate til mikrobiologisk fremstilling av humant serumalbumin og andre heterologe proteiner fra gjaer. - Google Patents

Fremgangsmaate til mikrobiologisk fremstilling av humant serumalbumin og andre heterologe proteiner fra gjaer.

Info

Publication number
NO893149L
NO893149L NO89893149A NO893149A NO893149L NO 893149 L NO893149 L NO 893149L NO 89893149 A NO89893149 A NO 89893149A NO 893149 A NO893149 A NO 893149A NO 893149 L NO893149 L NO 893149L
Authority
NO
Norway
Prior art keywords
serum albumin
humant
yours
procedure
microbiological preparation
Prior art date
Application number
NO89893149A
Other languages
English (en)
Norwegian (no)
Other versions
NO893149D0 (no
Inventor
Reinhard Fleer
Hiroshi Fukuhara
Patrice Yeh
Original Assignee
Rhone Poulenc Sante
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR8810615A external-priority patent/FR2635115B1/fr
Application filed by Rhone Poulenc Sante filed Critical Rhone Poulenc Sante
Publication of NO893149D0 publication Critical patent/NO893149D0/no
Publication of NO893149L publication Critical patent/NO893149L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
NO89893149A 1988-08-05 1989-08-03 Fremgangsmaate til mikrobiologisk fremstilling av humant serumalbumin og andre heterologe proteiner fra gjaer. NO893149L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8810615A FR2635115B1 (fr) 1988-08-05 1988-08-05 Procede de preparation de la serum albumine humaine a partir d'une levure
FR898908897A FR2649991B2 (fr) 1988-08-05 1989-07-03 Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces

Publications (2)

Publication Number Publication Date
NO893149D0 NO893149D0 (no) 1989-08-03
NO893149L true NO893149L (no) 1990-02-06

Family

ID=26226839

Family Applications (1)

Application Number Title Priority Date Filing Date
NO89893149A NO893149L (no) 1988-08-05 1989-08-03 Fremgangsmaate til mikrobiologisk fremstilling av humant serumalbumin og andre heterologe proteiner fra gjaer.

Country Status (13)

Country Link
EP (1) EP0361991B1 (fr)
JP (1) JP3068139B2 (fr)
KR (1) KR910004800A (fr)
AT (1) ATE187775T1 (fr)
AU (1) AU623425B2 (fr)
DE (1) DE68929115T2 (fr)
DK (1) DK175846B1 (fr)
FI (1) FI893702A7 (fr)
FR (1) FR2649991B2 (fr)
HU (1) HUT51329A (fr)
NO (1) NO893149L (fr)
NZ (1) NZ230229A (fr)
PT (1) PT91381B (fr)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2017176A1 (fr) * 1989-05-22 1990-11-22 Yoshitomi Pharmaceutical Industries Ltd. Plasmide contenant le gene de l'albumine, bacteries receptrices les contenant, production de ces bacteries et production de l'albumine
FR2676070B1 (fr) * 1991-04-30 1994-09-30 Rhone Poulenc Rorer Sa Promoteur de levure et son utilisation.
FR2678636A1 (fr) * 1991-07-02 1993-01-08 Rhone Poulenc Rorer Sa Procede de production de proteines recombinantes et cellules hote utilisees.
DE69230273T2 (de) 1991-07-12 2000-05-31 Dsm N.V., Heerlen Verfahren zur Reinigung von Serumalbumin
US5849874A (en) * 1991-07-12 1998-12-15 Gist-Brocades, N.V. Process for the purification of serum albumin
FR2679920A1 (fr) * 1991-08-02 1993-02-05 Rhone Poulenc Rorer Sa Levures recombinantes hautement stables pour la production de proteines recombinantes, leur preparation et leur utilisation.
FR2686620B1 (fr) * 1992-01-27 1995-06-23 Rhone Poulenc Rorer Sa Serum-albumine humaine, preparation et utilisation.
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2693475B1 (fr) * 1992-07-08 1994-09-02 Rhone Poulenc Rorer Sa Procédé d'identification et/ou de clonage de promoteurs transcriptionnels, et utilisation de ces promoteurs pour l'expression de gènes.
FR2693464B1 (fr) * 1992-07-08 1994-09-02 Rhone Poulenc Rorer Sa Promoteur de levure et son utilisation.
FR2693463B1 (fr) * 1992-07-08 1994-09-02 Rhone Poulenc Rorer Sa Promoteur de levure et son utilisation.
FR2694294B1 (fr) * 1992-07-30 1994-09-09 Rhone Poulenc Rorer Sa Promoteur de levure et son utilisateur.
DE4244915C2 (de) * 1992-08-14 1998-12-03 Widmar Prof Dr Tanner DNA-Moleküle codierend Proteine, die an der O-Glykosylierung von Proteinen beteiligt sind
US5728553A (en) * 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
CA2136564C (fr) * 1993-11-26 2008-04-08 Kaoru Kobayashi Mode de fabrication d'albumine serique humaine
DK0699687T3 (da) * 1994-08-31 2004-04-26 Mitsubishi Pharma Corp Fremgangsmåde til oprensning af rekombinant humant serumalbumin
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
ES2237551T3 (es) † 2000-02-08 2005-08-01 Allergan, Inc. Composiciones farmaceuticas que contienen toxina botulinica.
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US8632785B2 (en) 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP2292273A3 (fr) 2001-10-10 2011-11-23 BioGeneriX AG Remodelage et Glycoconjugaison de Peptides
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
WO2005003296A2 (fr) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Proteines hybrides d'albumine
CA2841097A1 (fr) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumine et proteines hybrides g-csf
KR100441384B1 (ko) * 2002-01-08 2004-07-21 주식회사 안지오랩 인간 혈청 알부민-팀프-2 융합 단백질 발현시스템 및재조합 인간 혈청 알부민-팀프-2 융합 단백질
US20060122374A1 (en) 2002-02-07 2006-06-08 Peter Mertins Albumin-fused anti-angiogenesis peptides
US7517671B2 (en) 2002-02-28 2009-04-14 New England Biolabs, Inc. Methods and compositions for concentrating secreted recombinant protein
CN101172091B (zh) 2007-09-25 2011-04-27 北京美福源生物医药科技有限公司 含人血清白蛋白与皮肤细胞生长因子的融合蛋白护肤产品制备工艺和用途
GB0217033D0 (en) 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
CA2522345A1 (fr) 2003-04-09 2004-11-18 Neose Technologies, Inc. Methode de glycopegylation et proteines/peptides produits au moyen de ces methodes
GB0329681D0 (en) * 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
US8591885B2 (en) 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
KR20080074120A (ko) 2005-10-13 2008-08-12 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
WO2008019368A2 (fr) 2006-08-07 2008-02-14 Teva Biopharmaceuticals Usa, Inc. Protéines de fusion d'albumine et d'insuline
EP2594583A1 (fr) 2007-08-08 2013-05-22 Novozymes Biopharma DK A/S Variants de transferrine et conjugues
CA2721202A1 (fr) 2008-04-17 2009-10-22 Hilde Adi Pierrette Revets Peptides capables de se lier a des proteines seriques et composes, constructions et polypeptides les comprenant
US8420051B2 (en) 2008-06-24 2013-04-16 Technische Universitaet Meunchen Muteins of hNGAL and related proteins with affinity for a given target
BRPI1004940A2 (pt) 2009-01-16 2018-06-19 Teva Pharma composição farmacêutica
SG172789A1 (en) 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
BR112012002709A2 (pt) 2009-08-05 2019-04-30 Pieris Ag formulações de liberação controlada de muteínas de lipocalina
BR112012013662B1 (pt) 2009-12-07 2022-08-02 Pieris Pharmaceuticals Gmbh Muteínas de lipocalina associada à gelatinase de neutrófilo humano (lcn2, hngal), seu uso e seus métodos de geração e produção, molécula de ácido nucleico, célula hospedeira, composição farmacêutica e kit de diagnóstico ou analítico
CA2784861A1 (fr) 2009-12-21 2011-07-14 Pharmathene, Inc. Butyrylcholinesterases recombinantes et produits de troncature de ceux-ci
AU2011263786B2 (en) 2010-06-08 2014-11-13 Astrazeneca Ab Tear lipocalin muteins binding IL-4 R alpha
AU2011290751B2 (en) 2010-08-16 2015-08-13 Pieris Ag Binding proteins for Hepcidin
CA2817779C (fr) 2010-11-15 2019-02-19 Pieris Pharmaceuticals Gmbh Muteines de lipocaline humaine 2 ayant de l'affinite pour le glypicane-3 (gpc3)
US9221885B2 (en) 2010-12-02 2015-12-29 Pieris Ag Muteins of human lipocalin 2 with affinity for CTLA-4
EP3453400B1 (fr) 2011-12-13 2021-01-20 Pieris Pharmaceuticals GmbH Méthodes de prévention ou de traitement de certains troubles par l'inhibition de la liaison d'il-4 et/ou il-13 à leurs récepteurs respectifs
WO2013174783A1 (fr) 2012-05-23 2013-11-28 Pieris Ag Mutéines de lipocaline avec affinité de liaison pour le glypican-3 (gpc-3) et utilisation de mutéines de lipocaline pour la délivrance spécifique de la cible aux cellules exprimant le gpc-3
IN2015DN01115A (fr) 2012-07-13 2015-06-26 Zymeworks Inc
EP2920202B1 (fr) 2012-11-19 2018-08-29 Pieris Pharmaceuticals GmbH Nouveaux polypeptides se liant specifiquement, et leur utilisation
WO2014113433A1 (fr) 2013-01-16 2014-07-24 George Mason University Cartographie de domaines de fixation
WO2014140210A1 (fr) 2013-03-14 2014-09-18 Pieris Ag Nouvelles protéines de fixation pour la pcsk9
US20140271538A1 (en) 2013-03-15 2014-09-18 Teva Pharmaceutical Industries Ltd. Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor for the Prevention of Neutropenia in Pediatric Patients
AU2015205530B8 (en) 2014-01-13 2019-09-19 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
EP3145945B1 (fr) 2014-05-22 2020-07-15 Pieris Pharmaceuticals GmbH Nouveaux polypeptides de liaison spécifique et utilisations associées
DE102014011653A1 (de) * 2014-06-20 2015-12-24 Ulrich Loos Nachweis von Autoantikörpern gegen den TSH-Rezeptor
CA2874083C (fr) 2014-12-05 2024-01-02 Universite Laval Polypeptides liant le tdp-43 utiles pour le traitement de maladies neurodegeneratives
SG11201705278QA (en) 2015-01-28 2017-07-28 Pieris Pharmaceuticals Gmbh Novel proteins specific for angiogenesis
EP3259282A1 (fr) 2015-02-18 2017-12-27 Sanofi Nouvelles protéines spécifiques de la pyoverdine et de la pyochéline
PH12017501583B1 (en) 2015-05-04 2023-01-20 Pieris Pharmaceuticals Gmbh Novel proteins specific for cd137
RU2727165C2 (ru) 2015-05-04 2020-07-21 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
DK3298030T5 (en) 2015-05-18 2024-10-07 Pieris Pharmaceuticals Gmbh Anti-cancerfusionspolypeptid
EP3298029A1 (fr) 2015-05-18 2018-03-28 Pieris Pharmaceuticals GmbH Mutéines de la lipocaline 2 humaine avec affinité pour glypican-3 (gpc3)
EP3298140B1 (fr) 2015-05-19 2024-04-24 Yale University Compositions pour le traitement d'états de calcification pathologique, et méthodes les utilisant
EP3115371A1 (fr) 2015-07-07 2017-01-11 Sanofi Molécules de fusion
MX2018000447A (es) 2015-07-15 2018-08-15 Pieris Pharmaceuticals Gmbh Novedosas proteinas especificas para lag-3.
US10703810B2 (en) 2015-11-30 2020-07-07 Pieris Australia Pty Ltd. Fusion polypeptides which bind vascular endothelial growth factor a (VEGF-A) and angiopoietin-2 (Ang-2)
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2018087108A1 (fr) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Protéines spécifiques de cd137
JP7225116B2 (ja) 2017-01-18 2023-02-20 ピエリス ファーマシューティカルズ ゲーエムベーハー Ｌａｇ－３に対する結合親和性を有するリポカリンムテイン
RS64343B9 (sr) 2018-07-31 2023-11-30 Pieris Pharmaceuticals Gmbh Novi fuzioni protein specifičan za cd137 i pd-l1
JP7476219B2 (ja) 2019-02-26 2024-04-30 ピエリス ファーマシューティカルズ ゲーエムベーハー Ｃｄ１３７およびｇｐｃ３に特異的な新規融合タンパク質
CA3177098A1 (fr) 2020-06-05 2021-12-09 Pieris Pharmaceuticals Gmbh Immunomodulateur multimere ciblant 4-1bb
AU2022253567A1 (en) 2021-04-08 2023-11-23 Pieris Pharmaceuticals Gmbh Novel lipocalin muteins specific for connective tissue growth factor (ctgf)
WO2022243341A1 (fr) 2021-05-18 2022-11-24 Pieris Pharmaceuticals Gmbh Mutéines de lipocaline ayant une affinité de liaison pour ox40
PE20251544A1 (es) 2022-09-21 2025-06-05 Seagen Inc Nueva proteina de fusion especifica para cd137 y cd228
WO2025175123A1 (fr) 2024-02-16 2025-08-21 Seagen Inc. Méthodes de traitement du cancer à l'aide de protéines de fusion spécifiques pour cd137 et cd228

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0079739A3 (fr) * 1981-11-12 1984-08-08 The Upjohn Company Nucléotides basés sur l'albumine, leur réplication et utilisation, et plasmides à utiliser à cet effet
EP0096910B1 (fr) 1982-05-19 1989-04-19 Unilever N.V. Levures du genre Kluyvéromyces, modifiées pour l'expression de préprothaumatine ou ses différentes formes alléliques ou modifiées ou leur formes de maturation
FR2532656B2 (fr) 1982-06-02 1985-10-18 Elf Bio Rech Nouveau vecteur de clonage et d'expression, levure et bacterie transformees par ce vecteur
FR2579223B1 (fr) 1985-03-25 1988-12-09 Genetica Procede de preparation microbiologique de la serum-albumine humaine
GB8510219D0 (en) 1985-04-22 1985-05-30 Bass Plc Isolation of fermentation products
JPS62215393A (ja) 1986-01-13 1987-09-22 ジエネツクス・コ−ポレ−シヨン バチルス中でのヒト血清アルブミンの製造
FR2594846B1 (fr) 1986-02-21 1989-10-20 Genetica Procede de preparation de la serum albumine humaine mature
IT1203758B (it) * 1986-03-27 1989-02-23 Univ Roma Vettori di clonazione e di espressione di geni eterologhi in lieviti e lieviti trasformati con tali vettori
GB8620926D0 (en) * 1986-08-29 1986-10-08 Delta Biotechnology Ltd Yeast promoter
ZA885536B (en) * 1987-07-28 1989-04-26 Gist Brocades Nv Kluyveromyces as a host strain
SE459586B (sv) * 1987-09-14 1989-07-17 Mta Szegedi Biolog Koezponti Strukturgen som kodar foer autentiskt humant serum albumin och foerfarande foer dess framstaellning
JP2791418B2 (ja) * 1987-12-02 1998-08-27 株式会社ミドリ十字 異種蛋白質の製造方法、組換えｄｎａ、形質転換体
IL89992A0 (en) * 1988-04-25 1989-12-15 Phillips Petroleum Co Expression of human serum albumin in methylotrophic yeasts
CA2017176A1 (fr) * 1989-05-22 1990-11-22 Yoshitomi Pharmaceutical Industries Ltd. Plasmide contenant le gene de l'albumine, bacteries receptrices les contenant, production de ces bacteries et production de l'albumine

Also Published As

Publication number Publication date
EP0361991A2 (fr) 1990-04-04
PT91381A (pt) 1990-03-08
FI893702L (fi) 1990-02-06
FI893702A0 (fi) 1989-08-04
HUT51329A (en) 1990-04-28
AU623425B2 (en) 1992-05-14
DK175846B1 (da) 2005-03-29
NO893149D0 (no) 1989-08-03
FI893702A7 (fi) 1990-02-06
FR2649991A2 (fr) 1991-01-25
DK383189A (da) 1990-02-06
KR910004800A (ko) 1991-03-29
DE68929115T2 (de) 2000-06-15
PT91381B (pt) 1995-05-31
EP0361991A3 (fr) 1992-10-14
AU3933289A (en) 1990-02-08
FR2649991B2 (fr) 1994-03-04
EP0361991B1 (fr) 1999-12-15
DK383189D0 (da) 1989-08-04
NZ230229A (en) 1991-07-26
ATE187775T1 (de) 2000-01-15
JP3068139B2 (ja) 2000-07-24
DE68929115D1 (de) 2000-01-20
JPH02276589A (ja) 1990-11-13

Similar Documents

Publication Publication Date Title
NO893149D0 (no) Fremgangsmaate til mikrobiologisk fremstilling av humant serumalbumin og andre heterologe proteiner fra gjaer.
AU588885B2 (en) Production of viral antigens
AU571128B2 (en) Expression of immunologically reactive aids viral protein
NO975434L (no) Fremgangsmåte for fremstilling av influensa hemagglutinin multivalente vaksiner
FI885679A0 (fi) Samuttryckning i eukariotiska celler.
GB8914968D0 (en) Production of virus and purification of viral envelope proteins for vaccine use
EP0769696A3 (fr) Anticorps et protéines d'essai d'une infection virale dans la vigne
AU1692595A (en) Mammalian expression systems for hepatitis c virus envelope genes
EP0248534A3 (fr) Méthode pour détecter une infection provoquée par le virus SIDA
AU2567888A (en) Hiv peptides and methods for detection of hiv
ES8505406A1 (es) Procedimiento de obtener y aislar hibridomas secretores de anticuerpos, procedimiento de obtener anticuerpos y metodo de obtener polipeptidos
IE860315L (en) Detecting htlv-iii neutralising antibodies
EP0315242A3 (fr) Procédé de purification des antigènes de l'hépatite obtenus par voie recombinante
DK326289A (da) Fremgangsmaade til fremstilling af et protein ud fra gaersvampe under anvendelse af et inducerbart system, samt vektorer og transformerede stammer til brug ved fremgangsmaaden
EP0381427A3 (fr) Composition de vaccin
EP0267622A3 (fr) Procédé pour la détection d'anticorps contre le virus de la leucémie des cellules T adultes
NZ222766A (en) Aids virus antigens: env/gag polypeptides: production by genetic engineering techniques: vaccines, and methods of diagnostic testing
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
EP0888046A4 (fr) Procede de production de proteine au moyen d'un systeme de traduction mitochondrique
WO1997027742B1 (fr) Procede de production de proteine au moyen d'un systeme de traduction mitochondrique
AU6262786A (en) Growing aids virus in cell lines lacking human class ii histocompatability antigens
ATE111954T1 (de) Verfahren zur transformation von menschlichen b- lymphocyten.
DK0592574T3 (da) Fremgangsmåde til fremstilling af rekombinante proteiner og værtsceller anvendt derved
WO1991008771A3 (fr) Procede de culture intensive, in vitro, de souches de babesia divergens, procede de preparation d'exoantigenes et vaccin contenant ces antigenes
SU1545614A1 (ru) Штамм гибридных культивируемых клеток животных mus musculus, используемый для получения моноклональных антител к белку е оболочки вирусов комплекса клещевого энцефалита